SQI Diagnostics Announces Stock Option Grants



    TORONTO, Feb. 27 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that pursuant to the Company's approved
Employee Stock Option Plan, it has granted 757,500 stock options to officers,
directors and employees of the Company. The options were granted at an
exercise price of $1.60 and expire February 27, 2013.

    About SQI Diagnostics

    SQI Diagnostics uses automation and proprietary miniaturization
technologies to significantly improve the economies of scale for laboratories
performing multiple biomarker testing at high volumes, allowing them to
deliver patient results faster using less labor and fewer resources. SQI
Diagnostics' platform has a user-friendly interface, 100% quality control,
high sample throughput and offers a more efficient alternative to current
testing options. SQI Diagnostics' initial products target the $1.4 billion
autoimmune disease market, with initial products for rheumatoid arthritis and
antiphospholipid syndrome scheduled for launch in 2008. SQI Diagnostics is
based in Toronto, Canada. For further information please visit
www.sqidiagnostics.com.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
statements.

    This release was prepared by management of the Company who takes full
    responsibility for its contents. The TSX Venture Exchange has not
    reviewed and does not accept responsibility for the adequacy or accuracy
    of this news release.

    %SEDAR: 00021000E




For further information:

For further information: Chief Financial Officer, Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Investor Relations, James
Smith, (416) 815-0700 ext. 229, jsmith@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890